Better Phase II Could Allow For More Single-Trial Approvals, Temple Says
Executive Summary
Increased emphasis on Phase II trials could improve drug development and potentially allow more drug approvals based on a single Phase III clinical trial, Center for Drug Evaluation & Research Associate Director for Medical Policy Robert Temple, MD, suggested Jan. 15